PRME
NASDAQ · Biotechnology
Prime Medicine Inc
$4.72
-0.52 (-9.92%)
Financial Highlights (FY 2026)
Revenue
5.56M
Net Income
-241,602,606
Gross Margin
—
Profit Margin
-4,342.4%
Rev Growth
—
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | — | 41.0% | 41.0% |
| Operating Margin | -4,498.1% | -6,108.6% | -25.3% | -24.4% |
| Profit Margin | -4,342.4% | -6,238.3% | -26.5% | -23.8% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 5.56M | 5.54M | 80.41M | 91.62M |
| Gross Profit | — | — | 32.97M | 37.56M |
| Operating Income | -249,964,526 | -338,694,143 | -20,351,737 | -22,374,485 |
| Net Income | -241,602,606 | -327,047,779 | -21,315,556 | -21,784,047 |
| Gross Margin | — | — | 41.0% | 41.0% |
| Operating Margin | -4,498.1% | -6,108.6% | -25.3% | -24.4% |
| Profit Margin | -4,342.4% | -6,238.3% | -26.5% | -23.8% |
| Rev Growth | — | -17.0% | +23.7% | +18.4% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 163.97M | 189.68M |
| Total Equity | — | — | 325.63M | 311.28M |
| D/E Ratio | — | — | 0.50 | 0.61 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -241,477,525 | -345,948,669 | -26,154,771 | -26,439,424 |
| Free Cash Flow | — | — | -13,660,015 | -13,547,044 |